What made Corvus stock double on Tuesday and is it sustainable?

Core Insights - Corvus Pharmaceuticals' shares more than doubled on January 20 following the announcement of positive Phase 1 trial data for its oral investigational drug, soquelitinib, aimed at treating atopic dermatitis [1] Company Summary - The significant increase in share price indicates strong investor confidence in the potential of soquelitinib as a treatment option for atopic dermatitis [1] - The positive trial results may position Corvus Pharmaceuticals favorably in the competitive dermatology market, particularly for conditions like atopic dermatitis [1]